HRP20120579T1 - Antagonisti receptora il-8 - Google Patents
Antagonisti receptora il-8 Download PDFInfo
- Publication number
- HRP20120579T1 HRP20120579T1 HRP20120579TT HRP20120579T HRP20120579T1 HR P20120579 T1 HRP20120579 T1 HR P20120579T1 HR P20120579T T HRP20120579T T HR P20120579TT HR P20120579 T HRP20120579 T HR P20120579T HR P20120579 T1 HRP20120579 T1 HR P20120579T1
- Authority
- HR
- Croatia
- Prior art keywords
- chloro
- phenyl
- urea
- hydroxy
- piperidinylsulfonyl
- Prior art date
Links
- 102000010681 interleukin-8 receptors Human genes 0.000 title 1
- 108010038415 interleukin-8 receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- -1 phenyloxy Chemical group 0.000 claims abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract 7
- 150000002367 halogens Chemical group 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 3
- YSPVHAUJXLGZHP-UHFFFAOYSA-N ethyl piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCCCC1 YSPVHAUJXLGZHP-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims abstract 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000004122 cyclic group Chemical group 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 108010012236 Chemokines Proteins 0.000 claims 6
- 102000019034 Chemokines Human genes 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 5
- 239000004202 carbamide Substances 0.000 claims 5
- NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- ZVDORRYGKFXKJT-UHFFFAOYSA-N 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperidin-3-ylsulfonylphenyl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CNCCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl ZVDORRYGKFXKJT-UHFFFAOYSA-N 0.000 claims 1
- MUYNMIWSABCFMR-UHFFFAOYSA-N 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperidin-4-ylsulfonylphenyl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CCNCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl MUYNMIWSABCFMR-UHFFFAOYSA-N 0.000 claims 1
- JPXNTZIAFODILH-UHFFFAOYSA-N 1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(pyrrolidin-3-ylmethylsulfonyl)phenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)CC2CNCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl JPXNTZIAFODILH-UHFFFAOYSA-N 0.000 claims 1
- CRHQLGHPEWNKIT-SECBINFHSA-N 1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-[(3r)-pyrrolidin-3-yl]sulfonylphenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@H]2CNCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl CRHQLGHPEWNKIT-SECBINFHSA-N 0.000 claims 1
- ZVDORRYGKFXKJT-JTQLQIEISA-N 1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@@H]2CNCCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl ZVDORRYGKFXKJT-JTQLQIEISA-N 0.000 claims 1
- CRHQLGHPEWNKIT-VIFPVBQESA-N 1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-[(3s)-pyrrolidin-3-yl]sulfonylphenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@@H]2CNCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl CRHQLGHPEWNKIT-VIFPVBQESA-N 0.000 claims 1
- PKYWPWXABSTTKQ-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-3-ylsulfonylphenyl)-3-(2-chloropyridin-3-yl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CNCCC2)C(O)=C1NC(=O)NC1=CC=CN=C1Cl PKYWPWXABSTTKQ-UHFFFAOYSA-N 0.000 claims 1
- MKXPBYCTEVMLQI-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-3-ylsulfonylphenyl)-3-(2-ethylphenyl)urea Chemical compound CCC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)C2CNCCC2)=C1O MKXPBYCTEVMLQI-UHFFFAOYSA-N 0.000 claims 1
- OHCFLELUXQCVDQ-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-3-ylsulfonylphenyl)-3-[2-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CNCCC2)C(O)=C1NC(=O)NC1=CC=CC=C1OC(F)(F)F OHCFLELUXQCVDQ-UHFFFAOYSA-N 0.000 claims 1
- QBBZZDIQIBBIPR-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-4-ylsulfonylphenyl)-3-(2,2-difluoro-1,3-benzodioxol-4-yl)urea Chemical compound OC1=C(NC(=O)NC=2C=3OC(F)(F)OC=3C=CC=2)C=CC(Cl)=C1S(=O)(=O)C1CCNCC1 QBBZZDIQIBBIPR-UHFFFAOYSA-N 0.000 claims 1
- AXDQQCQGTFACRR-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-4-ylsulfonylphenyl)-3-(2-chloropyridin-3-yl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CCNCC2)C(O)=C1NC(=O)NC1=CC=CN=C1Cl AXDQQCQGTFACRR-UHFFFAOYSA-N 0.000 claims 1
- VSFXNIKJSPGYDK-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-4-ylsulfonylphenyl)-3-(2-phenoxyphenyl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CCNCC2)C(O)=C1NC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 VSFXNIKJSPGYDK-UHFFFAOYSA-N 0.000 claims 1
- OCOZZPSPYJQSBG-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-4-ylsulfonylphenyl)-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)C2CCNCC2)=C1O OCOZZPSPYJQSBG-UHFFFAOYSA-N 0.000 claims 1
- UDEAWUIUSZJSEN-UHFFFAOYSA-N 1-(4-chloro-2-hydroxy-3-piperidin-4-ylsulfonylphenyl)-3-[2-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CCNCC2)C(O)=C1NC(=O)NC1=CC=CC=C1OC(F)(F)F UDEAWUIUSZJSEN-UHFFFAOYSA-N 0.000 claims 1
- MHTGRXKQMVYVCG-UHFFFAOYSA-N 1-[3-(azetidin-3-ylsulfonyl)-4-chloro-2-hydroxyphenyl]-3-(2-chloro-3-fluorophenyl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CNC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl MHTGRXKQMVYVCG-UHFFFAOYSA-N 0.000 claims 1
- OXIHKHMWVLOODK-UHFFFAOYSA-N 1-[3-(azetidin-3-ylsulfonyl)-4-chloro-2-hydroxyphenyl]-3-(2-chloropyridin-3-yl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)C2CNC2)C(O)=C1NC(=O)NC1=CC=CN=C1Cl OXIHKHMWVLOODK-UHFFFAOYSA-N 0.000 claims 1
- JQJOUUXCZZNDSH-UHFFFAOYSA-N 1-[3-(azetidin-3-ylsulfonyl)-4-chloro-2-hydroxyphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)C2CNC2)=C1O JQJOUUXCZZNDSH-UHFFFAOYSA-N 0.000 claims 1
- YQTOITXLXNUIOQ-UHFFFAOYSA-N 1-[4-chloro-2-hydroxy-3-(pyrrolidin-3-ylmethylsulfonyl)phenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)CC2CNCC2)=C1O YQTOITXLXNUIOQ-UHFFFAOYSA-N 0.000 claims 1
- UCTMKTXPZVSONA-UHFFFAOYSA-N 1-[4-chloro-2-hydroxy-3-(pyrrolidin-3-ylmethylsulfonyl)phenyl]-3-[2-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)CC2CNCC2)C(O)=C1NC(=O)NC1=CC=CC=C1OC(F)(F)F UCTMKTXPZVSONA-UHFFFAOYSA-N 0.000 claims 1
- NDGUODLRLFWGSS-CYBMUJFWSA-N 1-[4-chloro-2-hydroxy-3-[(3r)-pyrrolidin-3-yl]sulfonylphenyl]-3-(2-ethylphenyl)urea Chemical compound CCC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@H]2CNCC2)=C1O NDGUODLRLFWGSS-CYBMUJFWSA-N 0.000 claims 1
- RPNXJDDPJUHEGW-MRXNPFEDSA-N 1-[4-chloro-2-hydroxy-3-[(3r)-pyrrolidin-3-yl]sulfonylphenyl]-3-(2-phenoxyphenyl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@H]2CNCC2)C(O)=C1NC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 RPNXJDDPJUHEGW-MRXNPFEDSA-N 0.000 claims 1
- LMEJQAHYEIEWGL-SNVBAGLBSA-N 1-[4-chloro-2-hydroxy-3-[(3r)-pyrrolidin-3-yl]sulfonylphenyl]-3-[2-(trifluoromethoxy)phenyl]urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@H]2CNCC2)C(O)=C1NC(=O)NC1=CC=CC=C1OC(F)(F)F LMEJQAHYEIEWGL-SNVBAGLBSA-N 0.000 claims 1
- PKYWPWXABSTTKQ-JTQLQIEISA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(2-chloropyridin-3-yl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@@H]2CNCCC2)C(O)=C1NC(=O)NC1=CC=CN=C1Cl PKYWPWXABSTTKQ-JTQLQIEISA-N 0.000 claims 1
- RZKGHMMYGWXTOP-VIFPVBQESA-N 1-[4-chloro-2-hydroxy-3-[(3s)-pyrrolidin-3-yl]sulfonylphenyl]-3-(2-chloropyridin-3-yl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)[C@@H]2CNCC2)C(O)=C1NC(=O)NC1=CC=CN=C1Cl RZKGHMMYGWXTOP-VIFPVBQESA-N 0.000 claims 1
- FCPRZCUSHXUJGN-NSHDSACASA-N 1-[4-chloro-2-hydroxy-3-[(3s)-pyrrolidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCC2)=C1O FCPRZCUSHXUJGN-NSHDSACASA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- NEJBAMDKVNDHJM-UHFFFAOYSA-N ethyl 4-[6-chloro-2-hydroxy-3-[(2-phenoxyphenyl)carbamoylamino]phenyl]sulfonylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1S(=O)(=O)C1=C(Cl)C=CC(NC(=O)NC=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1O NEJBAMDKVNDHJM-UHFFFAOYSA-N 0.000 claims 1
- UNSQETVNQPAXKQ-UHFFFAOYSA-N ethyl 4-[6-chloro-3-[(2-chloro-3-fluorophenyl)carbamoylamino]-2-hydroxyphenyl]sulfonylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1S(=O)(=O)C1=C(O)C(NC(=O)NC=2C(=C(F)C=CC=2)Cl)=CC=C1Cl UNSQETVNQPAXKQ-UHFFFAOYSA-N 0.000 claims 1
- XIWDXADXPBRSJR-UHFFFAOYSA-N ethyl 4-[6-chloro-3-[(3-fluoro-2-methylphenyl)carbamoylamino]-2-hydroxyphenyl]sulfonylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1S(=O)(=O)C1=C(O)C(NC(=O)NC=2C(=C(F)C=CC=2)C)=CC=C1Cl XIWDXADXPBRSJR-UHFFFAOYSA-N 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79388106P | 2006-04-21 | 2006-04-21 | |
PCT/US2007/067091 WO2007124424A2 (en) | 2006-04-21 | 2007-04-20 | Il-8 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120579T1 true HRP20120579T1 (hr) | 2012-08-31 |
Family
ID=38625766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120579TT HRP20120579T1 (hr) | 2006-04-21 | 2012-07-12 | Antagonisti receptora il-8 |
Country Status (32)
Country | Link |
---|---|
US (4) | US7893089B2 (ko) |
EP (1) | EP2009992B1 (ko) |
JP (1) | JP5269763B2 (ko) |
KR (1) | KR101376472B1 (ko) |
CN (1) | CN101472477B (ko) |
AR (1) | AR060562A1 (ko) |
AU (1) | AU2007240365B2 (ko) |
BR (1) | BRPI0710232B8 (ko) |
CA (1) | CA2650009C (ko) |
CL (1) | CL2007001142A1 (ko) |
CR (1) | CR10391A (ko) |
CY (1) | CY1113132T1 (ko) |
DK (1) | DK2009992T3 (ko) |
EA (1) | EA014958B1 (ko) |
ES (1) | ES2389680T3 (ko) |
HK (1) | HK1123683A1 (ko) |
HR (1) | HRP20120579T1 (ko) |
IL (1) | IL194811A (ko) |
JO (1) | JO2796B1 (ko) |
MA (1) | MA30408B1 (ko) |
MX (1) | MX2008013600A (ko) |
MY (1) | MY145810A (ko) |
NO (1) | NO341736B1 (ko) |
NZ (1) | NZ572069A (ko) |
PE (1) | PE20080077A1 (ko) |
PL (1) | PL2009992T3 (ko) |
PT (1) | PT2009992E (ko) |
SI (1) | SI2009992T1 (ko) |
TW (1) | TWI414517B (ko) |
UA (1) | UA98456C2 (ko) |
WO (1) | WO2007124424A2 (ko) |
ZA (1) | ZA200808358B (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR041834A1 (es) * | 2002-10-29 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
US20070249625A1 (en) * | 2004-10-20 | 2007-10-25 | Jakob Busch-Petersen | Il-8 Receptor Antagonists |
KR101376472B1 (ko) * | 2006-04-21 | 2014-03-19 | 글락소스미스클라인 엘엘씨 | Il8 수용체 길항제 |
WO2007124423A2 (en) * | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
TW200817006A (en) * | 2006-06-23 | 2008-04-16 | Smithkline Beecham Corp | IL-8 receptor antagonist |
DK2356462T3 (en) | 2008-11-11 | 2017-02-27 | Univ Michigan Regents | ANTI-CXCR1 COMPOSITIONS AND PROCEDURES |
US8648070B2 (en) * | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
US8648118B2 (en) * | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
GB201320021D0 (en) | 2013-11-13 | 2013-12-25 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
CR20160529A (es) * | 2014-05-12 | 2017-01-02 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmacéuticas para tratar enfermedades infecciosas |
CR20160557A (es) * | 2014-05-29 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 |
JP2017527542A (ja) * | 2014-07-31 | 2017-09-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化学療法誘発末梢神経障害(cipn)の予防および/または治療のためのcxcr2アンタゴニストの使用 |
CN105061582A (zh) * | 2015-07-15 | 2015-11-18 | 云南大学 | 树鼩cxcl8-cxcr1在类风湿关节炎治疗的应用 |
KR20180086423A (ko) | 2015-11-30 | 2018-07-31 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 다니릭신의 정맥내 투여를 위한 제제 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US11136315B2 (en) | 2018-01-11 | 2021-10-05 | Medshine Discovery Inc. | CXCR2 antagonist |
WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
US20220340549A1 (en) * | 2019-07-11 | 2022-10-27 | Shenzhen Optimum Biological Technology Co., Ltd | Crystalline form of cxcr2 antagonist and application thereof |
CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1792156A (en) * | 1928-01-17 | 1931-02-10 | Gen Aniline Works Inc | 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them |
US2363074A (en) * | 1938-06-16 | 1944-11-21 | Geigy Ag J R | Halogen substituted acylamino sulphonic acids of the aromatic series and their manufacture |
US2407309A (en) * | 1942-02-04 | 1946-09-10 | Squibb & Sons Inc | Chemotherapeutic agents of the sulphonamide type |
US2795610A (en) * | 1955-03-31 | 1957-06-11 | Du Pont | Hydroxy-phenyl alkyl ureas |
BE639588A (ko) | 1962-11-06 | |||
US3996253A (en) * | 1966-01-11 | 1976-12-07 | Minnesota Mining And Manufacturing Company | Process for the preparation of color images |
GB1210596A (en) | 1967-04-06 | 1970-10-28 | Armour Grocery Products Compan | Antiseptic compositions |
CH506240A (de) | 1969-02-04 | 1971-04-30 | Ciba Geigy Ag | Verwendung von N-Hydroxyphenyl-N'-phenylharnstoffen zur Bekämpfung schädlicher Mikroorganismen ausserhalb der Textilindustrie |
SE370866B (ko) | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
US3647819A (en) * | 1969-09-19 | 1972-03-07 | Sterling Drug Inc | Indazolylphenylureas and indazolyl-phenylthioureas |
FR2100943A1 (en) | 1970-07-23 | 1972-03-24 | Ici Ltd | O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents |
US4048333A (en) * | 1971-08-23 | 1977-09-13 | Medizinska Akademia | Method for treating a picorna virus infection |
DE2303761A1 (de) | 1973-01-26 | 1974-08-01 | Henkel & Cie Gmbh | Neue n,n'-disubstituierte thioharnstoffe, deren herstellung sowie verwendung als antimikrobielle substanzen |
US4008326A (en) * | 1973-12-26 | 1977-02-15 | The Upjohn Company | Substituted ureas and thioureas and pharmaceutical compositions thereof |
US3932434A (en) | 1974-08-30 | 1976-01-13 | Eli Lilly And Company | N-2-(6-hydroxybenzothiazolyl)-N'-phenyl (or substituted phenyl) ureas |
JPS5598152A (en) | 1979-01-16 | 1980-07-25 | Hokko Chem Ind Co Ltd | Phenylurea derivative |
DE2928485A1 (de) * | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
GB2079480B (en) | 1980-07-08 | 1984-05-16 | Kodak Ltd | Heat-activated photographic and thermal recording processes employing precursor compounds |
US4608205A (en) * | 1983-03-09 | 1986-08-26 | American Cyanamid Company | Polyanionic benzene ureas |
US4591604A (en) | 1984-03-28 | 1986-05-27 | American Cyanamid Company | Method of inhibiting the complement system by administering multisulfonated naphthalene ureas |
JPH0678298B2 (ja) | 1988-03-30 | 1994-10-05 | ワーナー‐ランバート・コンパニー | N‐〔〔(2,6‐ジ置換)フエニル〕‐n′‐アリールアルキル〕尿素 |
US5215570A (en) | 1988-10-20 | 1993-06-01 | Ciba-Geigy Corporation | Sulfamoylphenylureas |
US5290814A (en) * | 1988-11-21 | 1994-03-01 | Burroughs Wellcome Co. | Anti-atherosclerotic diaryl compounds |
US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
JPH05294935A (ja) | 1991-03-15 | 1993-11-09 | Green Cross Corp:The | アミノピリジン系化合物 |
AU659861B2 (en) | 1991-09-10 | 1995-06-01 | Sansho Seiyaku Co., Ltd. | Preparation for promoting hair growth |
NZ250916A (en) * | 1993-02-27 | 1995-08-28 | Nihon Nohyaku Co Ltd | N-heteroaryl-n'-phenylureas, their use as acat inhibitors |
DK41193D0 (da) | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
US5312831A (en) * | 1993-05-12 | 1994-05-17 | American Cyanamid Company | Urethanes and ureas that induce cytokine production |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US5401758A (en) | 1993-10-07 | 1995-03-28 | Bristol-Myers Squibb Company | Pyridinyl cyanoguanidine compounds |
US5441984A (en) * | 1994-01-06 | 1995-08-15 | Eli Lilly And Company | Urea, thiourea and guanidine derivatives |
US5576335A (en) * | 1994-02-01 | 1996-11-19 | Nisshin Flour Milling Co., Ltd. | Urea derivatives and their use as ACAT inhibitors |
DE4413265A1 (de) * | 1994-04-16 | 1995-10-19 | Basf Ag | Hydroxyphenylharnstoffe |
US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
JP2000515495A (ja) | 1996-06-27 | 2000-11-21 | スミスクライン・ビーチャム・コーポレイション | Il―8レセプターアンタゴニスト |
US6218539B1 (en) | 1996-06-27 | 2001-04-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
CZ425698A3 (cs) * | 1996-06-27 | 1999-06-16 | Smithkline Beecham Corporation | Antagonista IL-8 receptoru |
KR20000022274A (ko) | 1996-06-27 | 2000-04-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Il-8 수용체 길항제 |
JP2000513359A (ja) | 1996-06-27 | 2000-10-10 | スミスクライン・ビーチャム・コーポレイション | Il―8受容体拮抗薬 |
EP0948330A4 (en) | 1996-08-06 | 1999-12-01 | Smithkline Beecham Corp | COOLING ANTENNA WITH CURVED SEGMENTS |
US6177448B1 (en) * | 1996-08-06 | 2001-01-23 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
WO1998005317A1 (en) * | 1996-08-06 | 1998-02-12 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
WO1998006262A1 (en) | 1996-08-15 | 1998-02-19 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
JP2000516621A (ja) * | 1996-08-15 | 2000-12-12 | スミスクライン・ビーチャム・コーポレイション | Il―8レセプターアンタゴニスト |
AR008290A1 (es) * | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. |
EP0920417A4 (en) | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
EP0939634A4 (en) | 1996-08-15 | 2001-02-21 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
JP2001501918A (ja) | 1996-08-21 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | Il―8レセプターアンタゴニスト |
CA2278504A1 (en) * | 1997-01-23 | 1998-07-30 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
US5929250A (en) | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6436927B1 (en) * | 1997-02-12 | 2002-08-20 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
CA2294064A1 (en) | 1997-07-29 | 1999-02-11 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
AR015426A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion |
EP1039903A4 (en) | 1998-01-16 | 2001-12-05 | Smithkline Beecham Corp | INTERLEUKIN-8 RECEPTOR ANTAGONISTS |
JP2002509106A (ja) * | 1998-01-20 | 2002-03-26 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体アンタゴニスト |
WO2000006557A1 (en) | 1998-07-27 | 2000-02-10 | Smithkline Beecham Corporation | Novel process for making il-8 receptor antagonists |
CA2341718A1 (en) | 1998-08-28 | 2000-03-09 | Neil H. Baine | An improved synthesis of 3-hydroxy-4-amino-benzonitrile |
CA2341711A1 (en) | 1998-08-28 | 2000-03-09 | Smithkline Beecham Corporation | Process for making 2-amino-5-cyanophenol |
HUP0103884A3 (en) * | 1998-09-23 | 2002-11-28 | Tularik Inc South San Francisc | Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use |
UY25842A1 (es) * | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
WO2000069435A1 (en) | 1999-05-18 | 2000-11-23 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
CO5170514A1 (es) * | 1999-05-28 | 2002-06-27 | Smithkline Beecham Corp | Antagonistas de los receptores de la il-8 nistas del receptor de la il-8 |
WO2000072800A2 (en) | 1999-05-28 | 2000-12-07 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
US20030225125A1 (en) * | 1999-06-16 | 2003-12-04 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6372933B1 (en) * | 1999-08-26 | 2002-04-16 | Smithkline Beecham Corporation | Process for preparing certain phenyl urea compounds |
US6440993B1 (en) * | 1999-10-12 | 2002-08-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
AU2001241896A1 (en) * | 2000-03-01 | 2001-09-12 | Smith Kline Beecham Corporation | Il-8 receptor antagonists |
WO2001068033A2 (en) * | 2000-03-10 | 2001-09-20 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
AR030273A1 (es) * | 2000-03-10 | 2003-08-20 | Smithkline Beecham Corp | Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina |
US6767922B2 (en) * | 2000-03-14 | 2004-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
CO5280089A1 (es) * | 2000-03-16 | 2003-05-30 | Smithkline Beecham Corp | Antagonistas del receptor il-8 |
US6664259B2 (en) * | 2000-03-16 | 2003-12-16 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
UY26627A1 (es) * | 2000-03-24 | 2001-09-28 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
US6653310B2 (en) * | 2000-04-07 | 2003-11-25 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
US7008962B2 (en) | 2000-05-30 | 2006-03-07 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
EP1351933B1 (en) * | 2001-01-16 | 2006-11-22 | SmithKline Beecham Corporation | Il-8 receptor antagonists |
DE60230722D1 (de) * | 2001-01-16 | 2009-02-26 | Smithkline Beecham Corp | Il-8-rezeptor-antagonisten |
US20030204085A1 (en) | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
AU2002303084B2 (en) | 2001-02-02 | 2006-05-25 | Pharmacopiea, Inc. | 3,4-di-substituted cyclobutene-1, 2 -diones as CXC chemokine receptor antagonists |
WO2002079122A2 (en) * | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Methods of synthesizing phenol-containing compounds |
US6720321B2 (en) | 2001-06-05 | 2004-04-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
US20040038854A1 (en) * | 2001-07-16 | 2004-02-26 | Dillon Susan B. | Use of il-8 receptor antagonists in the treatment of virus infections |
US20030032802A1 (en) * | 2002-08-30 | 2003-02-13 | Palovich Michael R. | IL8-receptor antagonists |
US20030028042A1 (en) * | 2002-08-30 | 2003-02-06 | Palovich Michael R. | Il8-receptor antagonists |
US20030065170A1 (en) * | 2002-09-05 | 2003-04-03 | Widdowson Katherine Louisa | Il-8 receptor antagonists |
AR041834A1 (es) * | 2002-10-29 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
JP2006527201A (ja) * | 2003-06-06 | 2006-11-30 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体アンタゴニスト |
JP2007537272A (ja) * | 2004-05-12 | 2007-12-20 | シェーリング コーポレイション | Cxcr1およびcxcr2ケモカインアンタゴニスト |
US20070249625A1 (en) * | 2004-10-20 | 2007-10-25 | Jakob Busch-Petersen | Il-8 Receptor Antagonists |
KR101376472B1 (ko) * | 2006-04-21 | 2014-03-19 | 글락소스미스클라인 엘엘씨 | Il8 수용체 길항제 |
WO2007124423A2 (en) * | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
TW200817006A (en) | 2006-06-23 | 2008-04-16 | Smithkline Beecham Corp | IL-8 receptor antagonist |
EP2099300A4 (en) | 2006-12-05 | 2011-12-07 | Glaxosmithkline Llc | IL-8 RECEPTOR ANTAGONISTS |
-
2007
- 2007-04-20 KR KR1020087028378A patent/KR101376472B1/ko active IP Right Grant
- 2007-04-20 NZ NZ572069A patent/NZ572069A/en not_active IP Right Cessation
- 2007-04-20 CA CA2650009A patent/CA2650009C/en not_active Expired - Fee Related
- 2007-04-20 WO PCT/US2007/067091 patent/WO2007124424A2/en active Application Filing
- 2007-04-20 ES ES07761018T patent/ES2389680T3/es active Active
- 2007-04-20 US US11/738,148 patent/US7893089B2/en not_active Expired - Fee Related
- 2007-04-20 BR BRPI0710232A patent/BRPI0710232B8/pt not_active IP Right Cessation
- 2007-04-20 TW TW096114156A patent/TWI414517B/zh not_active IP Right Cessation
- 2007-04-20 AU AU2007240365A patent/AU2007240365B2/en not_active Ceased
- 2007-04-20 UA UAA200812360A patent/UA98456C2/uk unknown
- 2007-04-20 MX MX2008013600A patent/MX2008013600A/es active IP Right Grant
- 2007-04-20 PL PL07761018T patent/PL2009992T3/pl unknown
- 2007-04-20 EA EA200870465A patent/EA014958B1/ru not_active IP Right Cessation
- 2007-04-20 US US12/297,885 patent/US20090093451A1/en not_active Abandoned
- 2007-04-20 AR ARP070101714A patent/AR060562A1/es unknown
- 2007-04-20 CN CN2007800232789A patent/CN101472477B/zh not_active Expired - Fee Related
- 2007-04-20 SI SI200730986T patent/SI2009992T1/sl unknown
- 2007-04-20 MY MYPI20084165A patent/MY145810A/en unknown
- 2007-04-20 PT PT07761018T patent/PT2009992E/pt unknown
- 2007-04-20 CL CL2007001142A patent/CL2007001142A1/es unknown
- 2007-04-20 DK DK07761018.6T patent/DK2009992T3/da active
- 2007-04-20 JP JP2009506795A patent/JP5269763B2/ja not_active Expired - Fee Related
- 2007-04-20 EP EP07761018A patent/EP2009992B1/en active Active
- 2007-04-22 JO JO2007159A patent/JO2796B1/en active
- 2007-04-23 PE PE2007000502A patent/PE20080077A1/es active IP Right Grant
-
2008
- 2008-10-01 ZA ZA2008/08358A patent/ZA200808358B/en unknown
- 2008-10-21 CR CR10391A patent/CR10391A/es unknown
- 2008-10-22 NO NO20084458A patent/NO341736B1/no not_active IP Right Cessation
- 2008-10-22 IL IL194811A patent/IL194811A/en active IP Right Grant
- 2008-11-10 MA MA31373A patent/MA30408B1/fr unknown
-
2009
- 2009-04-20 HK HK09103629.4A patent/HK1123683A1/xx not_active IP Right Cessation
-
2010
- 2010-11-12 US US12/944,902 patent/US20110059937A1/en not_active Abandoned
-
2011
- 2011-01-12 US US13/004,909 patent/US20110105563A1/en not_active Abandoned
-
2012
- 2012-07-12 HR HRP20120579TT patent/HRP20120579T1/hr unknown
- 2012-09-20 CY CY20121100863T patent/CY1113132T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120579T1 (hr) | Antagonisti receptora il-8 | |
JP2009534421A5 (ko) | ||
US8008305B2 (en) | TAAR1 ligands | |
OA12768A (en) | Nicotinamide derivatives useful as PDE4 inhibitors. | |
HRP20100153T1 (hr) | Antagonisti kemokin receptora | |
US20120196897A1 (en) | New compounds | |
IE60440B1 (en) | Herbicidal pyridine sulfonamides | |
JP2009536918A5 (ko) | ||
AU2018216954B2 (en) | Piperazine derivatives for influenza virus inhibition | |
JP2004523534A5 (ko) | ||
ZA200305535B (en) | Urea derivatives as integrin alpha 4 antagonists. | |
ZA200604485B (en) | Novel M3 muscarinic acetylcholine receptor antagonists | |
SK16152002A3 (sk) | Farmacueticky účinné piperidínové deriváty, najmä ako modulátory aktivity chemokínového receptora | |
RU2008122404A (ru) | Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1) | |
CN1335771A (zh) | 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物 | |
TW200307545A (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases | |
JP2008531690A5 (ko) | ||
JP2009534420A5 (ko) | ||
WO2003068233A1 (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases | |
CN103910663B (zh) | 一种具有抗菌活性的截短侧耳素衍生物及其制备和应用 | |
RU2008145871A (ru) | Антагонисты рецептора il-8 | |
JP4459622B2 (ja) | ピペリジン誘導体およびケモカイン・レセプター(特にccr5)活性モジュレーターとしてのその使用 | |
ES2295150T3 (es) | Derivados de enamina como moleculas de adhesion celular. | |
RU98114667A (ru) | 3-азетидинилалкилпиперидины или пирролидины в качестве антагонистов тахикинина | |
CZ20031013A3 (en) | Bridged piperazine derivatives |